Patients (n) | Proportion of patients (%) | ||
---|---|---|---|
Primary diseases | Chronic hepatitis C | 24 | 88.9 |
Melanoma | 2 | 7.4 | |
Erythrocytosis | 1 | 3.7 | |
Sex | Male | 12 | 44.4 |
Female | 15 | 55.6 | |
Age of sarcoidosis onset (mean ± standard deviation) | Overall: 51.4 ± 10.8 years Men: 48.3 ± 9.9 years Women: 53.9 ± 11.1 years | – | – |
Treatment | IFN-α + ribavirin | 21 | 77.8 |
IFN-α | 4 | 14.8 | |
IFN-α + ribavirin + others | 2 | 7.4 | |
Period until onset | 7.9 months (n = 24) (range, 2–14 months) | – | – |
Organ involvement | Skin | 23 | 85.1 |
Lung* | 19 | 70.1 | |
Lymphadenopathy (mediastinal) | 11 | 40.7 | |
Lymphadenopathy (hilar) | 11 | 40.7 | |
Lymphadenopathy (axillary) | 11 | 40.7 | |
Eye | 4 | 14.8 | |
Other (heart, liver, central nervous system, retroperitoneal lymphadenopathy, stomach, thyroid) | 3 Each 1 | 11.1 Each 3.7 | |
Therapy | Discontinuation of IFN | 16 | 59.2 |
Continuation of IFN | 2 | 25.9 | |
Already completed IFN treatment | 2 | 7.4 | |
Unknown | 2 | 7.4 | |
Topical steroid | 10 | 37.0 | |
Oral steroid | 8 | 29.6 | |
Steroid pulse | 2 | 7.4 | |
Others (permanent cardiac pacemaker) | 1 | 3.7 | |
Outcome | Resolution | 15 | 55.6 |
Improvement | 8 | 29.6 | |
No change | 2 | 7.4 | |
Death | 1 | 3.7 | |
Unknown | 1 | 3.7 |